Q-omics provides the consensus-scored DCTN4 profile across patient tissues and cancer cell-line models. DCTN4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, DCTN4 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, DCTN4 protein abundance shows 30,554 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, KIRC, and PDAC as cancer lineages where DCTN4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCTN4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCTN4 survival associations across molecular data types. DCTN4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCTN4 RNA expression–survival associations across cancer types. High DCTN4 expression shows unfavorable associations in HNSC, KICH, CESC and ESCA, but favorable associations in KIRC and COAD. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for DCTN4 RNA expression.
This table summarizes DCTN4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for DCTN4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCTN4 shows lower tumor expression in THCA and higher tumor expression in KIRC, LIHC, HNSC, COAD and BRCA. The KIRC box plot shows higher DCTN4 RNA expression in tumor versus normal tissue (log2 FC = +0.604, t-test p < 0.001).
This table shows molecular features associated with DCTN4 in patient tissues and cancer cell lines. In patient samples, DCTN4 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, DCTN4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
